Take Care,Operational Review - India
Key Highlights - Operational & Financial Performance (Q3 FY24)
Z
Clinical &
Operational
SRCC, Mumbai - Survivor of High-risk clinical condition:
11-year-old presented with super refractory status epilepticus which has an expected mortality of 50% &
expected disability of 80% was treated with Novel High dose Phenobarb therapy for 3 weeks. The patient
recovered without any disability.
Department of Orthopaedics and Trauma has started Hand Upper Limb Services & Elbow Arthroscopy during this
Quarter in Mazumdar Shaw Medical Centre (MSMC), Bengaluru
Mazumdar Shaw Medical Centre (MSMC), Bengaluru has successfully performed following procedures during the
quarter:
•
27 Solid Organ Transplants, 44 BMTs & 91 Robotic Procedures.
IM
Financial
Performance
•
•
•
2 very rare renal transplants of patients with Nephrocalcinosis - a genetic disorder.
Trans-Hepatic Cholangioscopy, first ever reported case in India.
100 complex trauma cases, 66 Robotic Ortho procedures.
Consolidated operating revenues of INR 12,036 mn in Q3 FY24, an increase of 6.7% YoY and decrease of 7.8% QoQ
Consolidated EBITDA of INR 2,968 mn in Q3 FY24 translating into EBITDA margin of 24.7% and consolidated PAT of
INR 1,881 mn at a PAT margin of 15.6%
Consolidated Total Borrowings less Cash, Bank Balance and Current Investments was - INR 251 mn (Net Cash) as on
31st December, 2023 i.e., net debt to equity ratio of - 0.01 (out of which, debt worth US$ 61 mn is foreign currency
denominated)
(1) As per the accounting treatment for leases per IND AS 116 effective 1st April 2019 which resulted in INR 176 mn increase in EBITDA for Q3 FY24
(2) As per the accounting treatment for leases per IND AS 116 effective 1st April 2019 which resulted in INR 5 mn increase in PAT for Q3 FY24
5View entire presentation